miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 16, 2025

Earnings week ahead: NVDA, WMT, HD, TGT, LOW, BIDU, ZIM, XPEV, and more

View original at seekingalpha.com
Earnings week ahead: NVDA, WMT, HD, TGT, LOW, BIDU, ZIM, XPEV, and more [Business and finance concept…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • XPEV's IRON robot appears more commercially advanced than Tesla's Optimus, positioning Xpeng as a forward-leaning player in China's EV-plus-robotics space

    80% confidence

  • Stifel moved to the sidelines on Home Depot and Lowe's ahead of seasonal slowdown and delayed recovery

    80% confidence

  • Home Depot has strong operations, geographic diversity, growing Pro segment, solid cash levels, and attractive valuation with a target of $422

    80% confidence

  • Foxconn already hit its 2025 AI server revenue goal

    80% confidence

  • Nvidia gross margins are expected to trend toward the mid-70% range by year-end

    80% confidence

  • Powerful AI infrastructure demand, record hyperscaler capex, and Nvidia's strong competitive position in both the U.S. and China will drive continued data center expansion and product refresh cycles, supporting a $351 price target

    80% confidence

  • Morgan Stanley sees bullish views on Nvidia ahead of earnings results

    80% confidence

  • Nvidia has visibility into $500B+ in Blackwell and Rubin revenue through CY26, signaling upside to current forecasts

    80% confidence

  • Nvidia's 28x P/S ratio is unsustainably high for a $5T company and growing global competition could erode margins, expecting a potential pullback toward $150–$170 by January

    80% confidence

  • XPeng shows strong innovation in humanoid robots, autonomous driving, and physical AI, along with improving gross margins now comparable to TSLA and BYD

    80% confidence

  • Home Depot's underperformance doesn't reduce risk, fundamentals remain disconnected from price, and rising dividend payout ratios appear unsustainable

    80% confidence

  • Susquehanna expects strong Nvidia FQ3 results as GB300 ramp accelerates and hyperscalers boost capex by 69% in 2025 and 24% in 2026

    80% confidence

  • Walmart will need meaningful margin expansion and faster growth to justify additional upside

    80% confidence

  • Walmart's rally has cooled as its premium ~39x forward P/E raises the bar for further upside; rising investments and intensifying competition are pressuring margins

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Earnings week ahead: NVDA, WMT, HD, TGT, LOW, BIDU, ZIM, XPEV, and more — Source | Via News | es.VIA.NEWS